Why the study?
Does treatment of malignant hypertension improve markers of endothelial dysfunction, platelet activation, and thrombogenesis?
Population
18 patients presenting with malignant hypertension (MHT) (15 male; mean age 48 ± 11) and 18 healthy controls.
Comparison
Antihypertensive treatment for 6 months vs Healthy controls and pre-treatment baseline
Design
Cohort
Follow-up
6 months
Authors
Loading...
MHT treatment may partially improve endothelial and platelet markers; hypothesis-generating and should not yet change practice.
Does treatment of malignant hypertension improve markers of endothelial dysfunction, platelet activation, and thrombogenesis?
Malignant hypertension is associated with endothelial dysfunction and abnormal hemorheology, which are partially reversed by 6 months of treatment.
Eiry Edmunds (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: